Selank acts as a positive allosteric modulator of GABA receptors, altering benzodiazepine activity
Background
Anxiety and mood disorders are major global health challenges, with current treatments often carrying significant side effects. Standard anxiolytics, which modulate the brain's GABA receptor system, are associated with dependence and memory impairment. This has spurred research into alternative, "mild" agents like neuropeptides. The heptapeptide Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is known for its prolonged anti-anxiety and nootropic effects, but its precise molecular mechanisms have been unclear. This study investigates how Selank interacts with the GABA system to produce its therapeutic benefits without the harsh side effects of traditional drugs.
Study Design
This study employed in vitro methods to explore Selank's molecular interactions. Researchers used the radioligand-receptor method of analysis as the primary technique to assess binding activity. They isolated plasmatic membranes from brain cells and determined protein concentrations in these samples. The purity of Selank and other reagents was verified using High-Performance Liquid Chromatography (HPLC). The core experiment involved measuring the binding of [3H]GABA to GABA receptors in the presence of Selank, benzodiazepines (like Diazepam), and Olanzapine, both alone and in combination, to characterize their joint effects on receptor modulation.
Results
Selank was found to be a positive allosteric modulator of the GABA receptor, affecting [3H]GABA binding. The peptide's interaction with the receptor is concentration-dependent and subtype selective. When co-administered, Selank and certain benzodiazepines regulate [3H]GABA binding in a unique, non-cumulative manner that differs from the effect of either substance alone. A key finding was that Selank is capable of blocking the modulatory activity of both Diazepam and Olanzapine on the GABA receptor.
This suggests that while Selank's binding site does not appear to be the same as that for these drugs, there may be a partial overlap, allowing it to interfere with their action. The results support the hypothesis that Selank's anxiolytic effects are mediated, at least in part, through this novel allosteric modulation of
GABAreceptors.
Key Findings
- Selank acts as a positive allosteric modulator, affecting [3H]GABA binding to GABA receptors.
- The joint action of Selank and benzodiazepines on GABA binding is not cumulative and differs from either drug alone.
- Selank can block the modulatory activity of Diazepam and Olanzapine on GABA receptors.
- The binding sites for Selank and drugs like Diazepam are likely distinct but may partially overlap.
- Selank's modulation of GABA receptors is concentration-dependent and subtype selective.
Why It Matters
The findings suggest Selank could offer a more nuanced approach to managing anxiety by modulating the GABA system differently than classic benzodiazepines. For biohackers and clinicians, this highlights Selank's potential as a standalone anxiolytic or as a co-agent that could alter the effects of conventional drugs. Selank may reduce the need for or mitigate side effects of benzodiazepines by blocking their activity while still providing anxiolysis through its own mechanism. This research is preclinical and based on receptor binding assays, meaning it's far from a usable clinical protocol. However, it provides a strong rationale for further investigation into combination therapies and Selank's specific receptor subtype interactions to optimize therapeutic outcomes.
TitrateLab articles covering Selank
Written by TitrateLab, separately from the study summarized above.
